1. Home
  2. CRON vs OPT Comparison

CRON vs OPT Comparison

Compare CRON & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRON
  • OPT
  • Stock Information
  • Founded
  • CRON 2012
  • OPT 1984
  • Country
  • CRON Canada
  • OPT Australia
  • Employees
  • CRON N/A
  • OPT N/A
  • Industry
  • CRON Medicinal Chemicals and Botanical Products
  • OPT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CRON Health Care
  • OPT Health Care
  • Exchange
  • CRON Nasdaq
  • OPT Nasdaq
  • Market Cap
  • CRON 804.7M
  • OPT 767.9M
  • IPO Year
  • CRON N/A
  • OPT 2020
  • Fundamental
  • Price
  • CRON $2.01
  • OPT $3.24
  • Analyst Decision
  • CRON Hold
  • OPT Strong Buy
  • Analyst Count
  • CRON 2
  • OPT 1
  • Target Price
  • CRON $3.00
  • OPT $12.00
  • AVG Volume (30 Days)
  • CRON 1.5M
  • OPT 39.0K
  • Earning Date
  • CRON 11-12-2024
  • OPT 08-30-2024
  • Dividend Yield
  • CRON N/A
  • OPT N/A
  • EPS Growth
  • CRON N/A
  • OPT N/A
  • EPS
  • CRON N/A
  • OPT N/A
  • Revenue
  • CRON $111,229,000.00
  • OPT $261,859.00
  • Revenue This Year
  • CRON $29.92
  • OPT N/A
  • Revenue Next Year
  • CRON $16.92
  • OPT $46,864.64
  • P/E Ratio
  • CRON N/A
  • OPT N/A
  • Revenue Growth
  • CRON 30.31
  • OPT N/A
  • 52 Week Low
  • CRON $1.85
  • OPT $1.79
  • 52 Week High
  • CRON $3.14
  • OPT $5.45
  • Technical
  • Relative Strength Index (RSI)
  • CRON 42.95
  • OPT 27.29
  • Support Level
  • CRON $1.91
  • OPT $4.02
  • Resistance Level
  • CRON $2.34
  • OPT $4.18
  • Average True Range (ATR)
  • CRON 0.11
  • OPT 0.22
  • MACD
  • CRON -0.01
  • OPT -0.13
  • Stochastic Oscillator
  • CRON 23.26
  • OPT 6.85

About CRON Cronos Group Inc. Common Share

Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the US, the company has an option to acquire 5.9% of US multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.

About OPT Opthea Limited

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.

Share on Social Networks: